4D Molecular Therapeutics, Inc. Operating Income Loss

• 4D Molecular Therapeutics, Inc. showed an increase of +15.1% in Operating Income Loss from 2024 to 2025.
• This data is from 4D Molecular Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), 4D Molecular Therapeutics, Inc.'s Operating Income Loss has declined by 214.3%.
• Historical annual values: Fiscal year 2025: -$159.55 million | Fiscal year 2024: -$187.84 million | Fiscal year 2023: -$112.87 million | Fiscal year 2022: -$110.03 million | Fiscal year 2021: -$71.33 million | Fiscal year 2020: -$56.66 million | Fiscal year 2019: -$50.76 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026